Saroja Pharma Industries India Limited

Saroja Pharma Industries India Limited (SAROJA) is a micro-cap Chemicals company valued at ₹16 crore operating in Specialty Chemicals on the NSE and BSE.

Recent price move

Saroja Pharma Industries India Limited last traded at ₹40.8, unchanged on the day.

Recent developments

2026-09-07: The DocStoX score increased to 4.3, but the verdict remained 'avoid' due to weak earnings growth. 2026-07-16: The score was 3.2, indicating continued concerns about the company's fundamentals despite some positive trends.

Financial performance

The company's business is improving, with annual revenue rising 30.7% and net profit growing 57.3% year-on-year. However, the latest quarter saw revenue fall 10.4% compared to the same quarter a year earlier, while net profit rose 48.6%. Margins have improved, with the net profit margin up 0.4 percentage points to 2.3%, and returns remain stable at 9.8% return on equity and 13.0% return on capital employed.

Valuation multiples

The stock trades at 10.1 times earnings, 0.93 times book value.

Things to watch

The company has not paid dividends despite reporting profits, which could signal financial pressure or a lack of cash flow. The stock is trading 20.9% below its 52-week high, suggesting potential investor skepticism. The company's earnings growth score is very low, indicating limited confidence in its ability to sustain profitability.

Where it stands

The DocStoX verdict of 'avoid' follows from the company's weak earnings growth and lack of dividend payouts, despite positive revenue and margin trends. The most critical factor is the low earnings growth score, which undermines investor confidence despite improving operational metrics.

Summarised by DocStoX's model on 2026-09-08 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.